Two Sigma Advisers
KLRS

Two Sigma Advisers’s Kalaris Therapeutics KLRS Stock Holding History

Two Sigma Advisers’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,281
Closed -$54.1K – 2691
2025
Q2 		$54.1K Sell
20,281
-1,300
-6% -$5.87K ﹤0.01% 2249
2025
Q1 		$173K Sell
21,581
-6
-0% -$59 ﹤0.01% 2170
2024
Q4 		$209K Sell
21,587
-513
-2% -$7.76K ﹤0.01% 2115
2024
Q3 		$411K Sell
22,100
-5,465
-20% -$95.6K ﹤0.01% 1782
2024
Q2 		$459K Buy
27,565
+14,591
+112% +$258K ﹤0.01% 1917
2024
Q1 		$225K Buy
12,974
+8,678
+202% +$142K ﹤0.01% 2176
2023
Q4 		$67.2K Buy
+4,296
New +$169K ﹤0.01% 2371
2022
Q4 		– Sell
-491
Closed -$89K – 2733
2022
Q3 		$89K Sell
491
-1,187
-71% -$185K ﹤0.01% 2322
2022
Q2 		$151K Buy
1,678
+430
+34% +$45.1K ﹤0.01% 2334
2022
Q1 		$194K Buy
1,248
+687
+122% +$137K ﹤0.01% 2390
2021
Q4 		$167K Buy
+561
New +$260K ﹤0.01% 2332

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Two Sigma Advisers's KLRS Position: Q3 2025 in Review

Two Sigma Advisers sold out of Kalaris Therapeutics (KLRS) in Q3 2025, closing a stake of 20,281 shares — an estimated $54.1K sold.

Two Sigma Advisers first reported a position in KLRS in Q4 2021 and held it in 11 quarters. The position peaked at $459K in Q2 2024. 32 funds tracked by Wall St. Rank hold KLRS as of Q3 2025.

  • Two Sigma Advisers reported no remaining Kalaris Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 20,281 Kalaris Therapeutics shares in Q3 2025, an estimated $54.1K.
  • Two Sigma Advisers first reported a position in Kalaris Therapeutics in Q4 2021 and held it in 11 quarters.
  • Two Sigma Advisers's Kalaris Therapeutics position peaked at $459K in Q2 2024.
  • 32 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2025.

Based on Two Sigma Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.